These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 35081734)

  • 1. Real-world outcomes with second-line therapy in advanced esophageal squamous cell carcinoma using SEER-Medicare data.
    Danese M; Gricar J; Abraham P
    Future Oncol; 2022 Mar; 18(8):927-936. PubMed ID: 35081734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Treatment Patterns and Outcomes in Patients Receiving Second-Line Therapy for Advanced/Metastatic Esophageal Squamous Cell Carcinoma.
    Abraham P; Gricar J; Zhang Y; Shankaran V
    Adv Ther; 2020 Jul; 37(7):3392-3403. PubMed ID: 32533533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial.
    Luo H; Lu J; Bai Y; Mao T; Wang J; Fan Q; Zhang Y; Zhao K; Chen Z; Gao S; Li J; Fu Z; Gu K; Liu Z; Wu L; Zhang X; Feng J; Niu Z; Ba Y; Zhang H; Liu Y; Zhang L; Min X; Huang J; Cheng Y; Wang D; Shen Y; Yang Q; Zou J; Xu RH;
    JAMA; 2021 Sep; 326(10):916-925. PubMed ID: 34519801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.
    Huang J; Xu J; Chen Y; Zhuang W; Zhang Y; Chen Z; Chen J; Zhang H; Niu Z; Fan Q; Lin L; Gu K; Liu Y; Ba Y; Miao Z; Jiang X; Zeng M; Chen J; Fu Z; Gan L; Wang J; Zhan X; Liu T; Li Z; Shen L; Shu Y; Zhang T; Yang Q; Zou J;
    Lancet Oncol; 2020 Jun; 21(6):832-842. PubMed ID: 32416073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of tislelizumab vs. camrelizumab for the treatment of second-line locally advanced or metastatic esophageal squamous cell carcinoma.
    Chen P; Fu C; Shen L; Fei Z; Luo M; Chen Y; Li H
    BMC Health Serv Res; 2024 May; 24(1):676. PubMed ID: 38807104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical features and treatment outcomes of PD-1 inhibitor therapy in elderly patients (≥ 65 years) with advanced esophageal squamous cell carcinoma: a real-world study.
    Yu Y; Wu T; Gan W; Liu C; Zhang R; Zheng J; Xiong J; Chen J; Li J
    Clin Transl Oncol; 2024 Sep; 26(9):2360-2368. PubMed ID: 38602642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overall Survival of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Treated with Nimotuzumab in the Real World.
    Saumell Y; Sanchez L; González S; Ortiz R; Medina E; Galán Y; Lage A
    Adv Ther; 2017 Dec; 34(12):2638-2647. PubMed ID: 29134427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human endostatin plus paclitaxel/nedaplatin for recurrent or metastatic advanced esophageal squamous cell carcinoma: a prospective, single-arm, open-label, phase II study.
    Wang ZQ; Wang DS; Wang FH; Ren C; Tan Q; Li YH
    Invest New Drugs; 2021 Apr; 39(2):516-523. PubMed ID: 33070249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pembrolizumab for recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus: a drug safety evaluation.
    Yamamoto K; Yamamoto S; Kato K
    Expert Opin Drug Saf; 2024 Jun; 23(6):667-675. PubMed ID: 38676380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy.
    Shirakawa T; Kato K; Nagashima K; Nishikawa A; Sawada R; Takahashi N; Shoji H; Sasaki Y; Honma Y; Iwasa S; Takashima A; Okita N; Hamaguchi T; Yamada Y; Shimada Y
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1207-15. PubMed ID: 25267597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma.
    Xu J; Bai Y; Xu N; Li E; Wang B; Wang J; Li X; Wang X; Yuan X
    Clin Cancer Res; 2020 Sep; 26(17):4542-4550. PubMed ID: 32561664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world outcomes in patients with first-line and second-line therapy for advanced esophageal squamous cell carcinoma.
    Ahn D; Sidel M; Panattoni L; Sacks N; Hernandez J; Villacorta R
    Future Oncol; 2022 Sep; 18(30):3419-3433. PubMed ID: 36098270
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2).
    Xu J; Li Y; Fan Q; Shu Y; Yang L; Cui T; Gu K; Tao M; Wang X; Cui C; Xu N; Xiao J; Gao Q; Liu Y; Zhang T; Bai Y; Li W; Zhang Y; Dai G; Ma D; Zhang J; Bai C; Huang Y; Liao W; Wu L; Chen X; Yang Y; Wang J; Ji S; Zhou H; Wang Y; Ma Z; Wang Y; Peng B; Sun J; Mancao C
    Nat Commun; 2022 Feb; 13(1):857. PubMed ID: 35165274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and survival of nivolumab treatment for recurrent/unresectable esophageal squamous-cell carcinoma: real-world clinical data from a large multi-institutional cohort.
    Makino T; Nakai S; Momose K; Yamashita K; Tanaka K; Miyata H; Yamamoto S; Motoori M; Kimura Y; Ushimaru Y; Hirao M; Matsuyama J; Akamaru Y; Kurokawa Y; Eguchi H; Doki Y
    Esophagus; 2024 Jul; 21(3):319-327. PubMed ID: 38717686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer.
    Kehl KL; Greenwald S; Chamoun NG; Manberg PJ; Schrag D
    JAMA Netw Open; 2021 May; 4(5):e2111113. PubMed ID: 34019086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
    Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J
    Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial.
    Meng X; Wu T; Hong Y; Fan Q; Ren Z; Guo Y; Yang X; Shi P; Yang J; Yin X; Luo Z; Xia J; Zhou Y; Xu M; Liu E; Jiang G; Li S; Zhao F; Ma C; Ma C; Hou Z; Li J; Wang J; Wang F
    Lancet Gastroenterol Hepatol; 2022 Mar; 7(3):245-253. PubMed ID: 34998471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy and predictors of pembrolizumab-based regimens in patients with advanced esophageal cancer in the real world.
    Wang HC; Huang X; Chen J; Li Y; Cong Y; Qu BL; Feng SQ; Liu F
    World J Gastroenterol; 2023 Nov; 29(41):5641-5656. PubMed ID: 38077159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma.
    Zhao J; Lei J; Yu J; Zhang C; Song X; Zhang N; Wang Y; Zhang S
    Invest New Drugs; 2020 Apr; 38(2):500-506. PubMed ID: 31650447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress in second-line antibody therapies for advanced esophageal squamous cell carcinoma.
    Ogura N; Yamamoto S; Kato K
    Expert Opin Biol Ther; 2024 Jun; 24(6):503-509. PubMed ID: 38860728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.